Ravi menon, Indian film actor

, a leading global Pharmacovigilance services company that brings together safety, medical, regulatory and technology resources to ensure that patients receive the safest, most effective therapies possible, has announced the appointment of Dr TakuSeriu - a globally respected scientist and business leader in the pharmaceutical industry - as Senior Adviser to the Board of Directors of APCER. Dr TakuSeriu commented, "The pandemic has intensified the criticality of pharmacovigilance as a discipline in light of emergency use approvals. As the regulatory norms evolve and become increasingly stringent, I look forward to helping APCER to be at the forefront of the emerging paradigm where customers and regulators expect high levels of quality and scientific expertise, as also a continuous improvement from people, processes and technology perspective." Dr Seriu has been the head of various functions, globally and for Japan, including Clinical Development, Medical Affairs, Pharmacovigilance, Regulatory Affairs and Quality Assurance at multinational pharmaceutical compes such as Schering AG (now Bayer) and Bristol-Myers Squibb. Most recently at Otsuka Pharmaceutical Co., Ltd., Dr Seriu was part of the global senior leadership and a Board Member. Dr Seriu is a Board-certified Hematologist, Gastroenterologist, Fellow and member of the Japanese Society of Internal Medicine, and Director of the Japanese Association of Pharmaceutical Medicine. He also managed international oncology research projects as Medical Research Scientist at the University of Heidelberg and the University of Ulm, in Germany. Ravi Menon, Chairman, said, "We appreciate having the opportunity to draw on the insights and perspectives arising out of Taku-san's broad and deep experience, both as a scientist and as a business leader. As we look to build APCER to greater heights, and to position ourselves for the challenges and opportunities ahead of us, Taku-san's counsel and guidance will enable us to deliver improved outcomes for our customers, staff and other stakeholders, and further strengthen our market positioning, with a particular focus on the emerging therapies segment."This story is provided by BusinessWire India. will not be responsible in any way for the content of this article. (/BusinessWire India)( With inputs from ANI )Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

Ravi Menon, NewsFOLLOW

Ravi menon, Latest News

Calling India a strong leader in IT and fintech sector, Minister of Trade and Industry Singapore Gan Kim Yong ... ...

Ravi Menon, Managing Director of the Monetary Authority of Singapore central bank said even though various central banks have ... ...

Decarbonisation is a costly affair and it is imperative to act fast to finance the transition to net-zero emission ... ...

Singapore's central bank Monetary Authority of Singapore is contemplating adding frictions on retail access to cryptocurrencies through various measures including customer suitability tests and restricting the use of leverage and credit facilities fo ...

Singapore, July 19 Amid the global crypto meltdown, Singapore, which has a clear licensing and regulatory framework, is ... ...

SOBHA, India's most credible and admired real estate brand is introducing SOBHA Townpark at Yadavanahalli, Bengaluru. ...

APCER, a leading global Pharmacovigilance services company that brings together safety, medical, regulatory and technology resources to ensure that patients receive the safest, most effective therapies possible, has announced the appointment of Dr Ta ...